ライフサイエンスコーパス: cross-reactive

1 n for shared human CDR3betas that are highly cross-reactive.

2 ide binding, the ILA1 T-cell clone was still cross-reactive.

3 nigmatic: TCRs are at once specific but also cross-reactive.

4 bor intensive, and the resulting TCRs may be cross-reactive.

5 CMV epitopes, either conserved, variant, or cross-reactive.

6 a human anti-CD3 specificity that is rhesus cross-reactive.

7 at NA immunity can be protective and broadly cross-reactive.

8 N immunizations elicit serotype-specific and cross-reactive Ab and T cell responses.

9 associated with more-severe disease, and no cross-reactive Abs against prior betacoronavirus were fo

10 results suggest that DENV NS1 can induce Plg cross-reactive Abs through molecular mimicry, which can

11 hila to determine whether NS1 can induce Plg cross-reactive Abs.

12 Furthermore, the magnitude of HIV-1 cross-reactive ADCC activity during HIV-2 infections dep

13 Moreover, detection of this cross-reactive Ag by B6 AM14 Vkappa8 B cells promotes an

14 Anti-HA antibodies were cross-reactive against multiple subtypes, and some showe

15 ing the pIP501 plasmid and also proved to be cross-reactive against other clinically relevant enteroc

16 ve long been diagnosed with serum antibodies cross-reactive against Proteus vulgaris (Weil-Felix reac

17 Tandem mass spectrometry identified the cross-reactive allergens as Der f 15 in HDM, two homolog

18 small number of amino acid differences among cross-reactive allergens can reduce the affinity of bind

19 ed to be termed 'fish-chicken syndrome' with cross-reactive allergens involved being parvalbumins, en

20 Furthermore, Gal d 7-cross-reactive allergens were also detected in other pou

21 at commercial Cpn and Ctr ELISA antigens are cross-reactive among all Chlamydia spp., but Cpn and Ctr

22 The responses were robust and cross-reactive and contained antibodies specific to mult

23 tive Ags (COBRA) targeting H1 elicit a broad cross-reactive and cross-neutralizing Ab response agains

24 otential of the human immune system to mount cross-reactive and cross-protective humoral immune respo

25 of heterogeneous and functionally competent cross-reactive and induced memory CD8(+) T cell response

26 These results define cross-reactive and induced SARS-CoV-2-specific CD8(+) T

27 Furthermore, we notice that hC3Nb2 is cross-reactive and inhibits the lectin and alternative p

28 Anti-Flavivirus antibodies are highly cross-reactive and may facilitate Zika virus (ZIKV) infe

29 sing features of IgA, being at the same time cross-reactive and selective in its interactions with th

30 les to estimate the contribution of serotype-cross-reactive and type-specific antibodies to neutraliz

31 lated flaviviruses has long been known to be cross-reactive, and antibody detection of ZIKV is nonspe

32 conclusion, TXB2 is a high affinity, species cross-reactive, and brain-selective VNAR antibody to TfR

33 We selected a high-affinity monkey cross-reactive anti-CLL-1 arm and tested several anti-CD

34 llenge in dengue vaccine development is that cross-reactive anti-DENV Abs can be protective or potent

35 raries demonstrated that biopannng against a cross-reactive anti-Luk monoclonal antibody (MAb) recove

36 etermine whether the specificities of a less cross-reactive anti-Zaire ebolavirus sdAb and a totally

37 t regimen, resulting in a high proportion of cross-reactive antibodies (25%).

38 into dengue virus (DENV) endemic regions and cross-reactive antibodies (Abs) could potentially affect

39 er was based on a virus that elicits broadly cross-reactive antibodies against a wide range of H5 vir

40 1 glycoconjugate resulted in high titers of cross-reactive antibodies against CR-Kp CPS in mice and

41 nd ability of the vaccines to elicit broadly cross-reactive antibodies against the hemagglutinin stal

42 etting the concern of ZIKV vaccines inducing cross-reactive antibodies and sensitizing people to subs

43 duced the exposure of epitopes recognized by cross-reactive antibodies and therefore showed a lower p

44 Ad5 vaccine induced dominant gp41-microbiota cross-reactive antibodies derived from blood memory B ce

45 Our work indicates that these cross-reactive antibodies have the potential to cause an

46 envelope proteins raise the possibility that cross-reactive antibodies induced following Zika virus i

47 ines as the induction of poorly neutralizing cross-reactive antibodies may prime an individual for AD

48 o influenza and suggests that once elicited, cross-reactive antibodies targeting the HA stem can pers

49 a virus vaccine candidates to induce broadly cross-reactive antibodies targeting the stalk domain of

50 d to identify conserved HA epitope selecting cross-reactive antibodies that mediate heterosubtypic pr

51 Of note, intertype cross-reactive antibodies that mediated HIV-1 envelope g

52 isk, we evaluated the levels of heterologous cross-reactive antibodies to A(H3N2)v cluster 2010.1 vir

53 isk, we evaluated the levels of heterologous cross-reactive antibodies to A(H3N2)v cluster 2010.1 vir

54 fluenza vaccine would need to elicit broadly cross-reactive antibodies to multiple H2 influenza virus

55 al survey using a novel approach to rule out cross-reactive antibodies to other seasonal influenza vi

56 d sGP in complex with GP-specific and GP/sGP cross-reactive antibodies undergoing human clinical tria

57 The presence of partially cross-reactive antibodies with other betacoronaviruses i

58 pe on envelope (E) protein-are recognized by cross-reactive antibodies(1-3) that are not only poorly

59 The latter, largely serotype-cross-reactive antibodies, demonstrated increased stabil

60 VP1-specific, cross-reactive antibodies, especially those with ADCP ac

61 might continue to circulate, and to generate cross-reactive antibodies, particularly towards conserve

62 VAR2CSA, showing that PvDBP can give rise to cross-reactive antibodies.

63 served antigenic sites recognized by broadly cross-reactive antibodies.

64 nd DENV3 were mainly neutralized by serotype cross-reactive antibodies.

65 infections and vaccinations may induce these cross-reactive antibodies.

66 ine efficacy could be improved by exploiting cross-reactive antibodies.

67 Guinea pigs developed high titers of broadly cross-reactive antibodies; mice and ferrets exhibited na

68 immunoassay-like setting by capturing with a cross-reactive antibody (R109) binding to both proteins

69 Here, we examine the structural basis for cross-reactive antibody binding to RSV and HMPV F protei

70 differences in the degree of homologous and cross-reactive antibody boosting elicited by different e

71 By evaluating the cross-reactive antibody response to the H10 viruses and

72 a on weight loss, viral replication, and the cross-reactive antibody response, we identified A/mallar

73 ble infection; however, we could not exclude cross-reactive antibody responses to seasonal influenza

74 Anhui/1/2005 (clade 2.3.4) vaccine to elicit cross-reactive antibody responses to these emerging viru

75 c germinal centers give rise to more broadly cross-reactive antibody responses, thereby generating cr

76 irus (DENV) and Zika virus (ZIKV) can induce cross-reactive antibody responses.

77 ple unobserved prior infections that produce cross-reactive antibody responses.

78 Unexpectedly, Pca1 immunization generated cross-reactive antibody that recognized Pneumocystis jir

79 predicts the presence of SARS-CoV/SARS-CoV-2 cross-reactive antibody titers specific for the receptor

80 We describe 12 patients positive for the cross-reactive antibody, compared with a negative group

81 h both an sGP-specific antibody and a GP/sGP cross-reactive antibody, permits us to unambiguously ass

82 nactivated A(H7N9) vaccines elicited robust, cross-reactive antibody-dependent cell-mediated cytotoxi

83 current study we examined type-specific and cross-reactive antibody-dependent cellular cytotoxicity

84 n Lactobacillus casei over-expressing myosin-cross-reactive antigen (LC(+mcra)).

85 tis surface protein, designated Pneumocystis cross-reactive antigen 1 (Pca1), as a potential vaccine

86 l prophage in stools and expression of a TMP-cross-reactive antigen by tumors correlated with long-te

87 tients were more likely to seroconvert for a cross-reactive antigen if they seroconverted for the spe

88 be taken into account when designing broadly cross-reactive antivirals against NoVs.IMPORTANCE Human

89 nodominance and allows otherwise subdominant cross-reactive B cell responses to emerge.

90 the phenotype of DENV serotype-specific and cross-reactive B cells during and after natural DENV inf

91 DENV serotype-specific and cross-reactive B cells were identified in PBMCs from all

92 eterotypic, provides an avidity advantage to cross-reactive B cells.

93 -class sequences were recovered from >40% of cross-reactive B cells.

94 R-HPVs, including finding 3 broadly antibody cross-reactive BCEs of L1 that each covers almost all HR

95 mmunodominant CD8 T cell response apparently cross-reactive between a newly defined putative MCMV epi

96 Several epitopes were cross-reactive between isoallergens and ragweed species,

97 lidated immunogenic B-cell epitopes that are cross-reactive between members of the pore-forming leuko

98 from the receptor binding site, that enables cross-reactive binding between SARS-CoV-2 and SARS-CoV.

99 ils parallel selection to selectively enrich cross-reactive binding sequences, followed by serial sel

100 nteracting residues that contribute to weak, cross-reactive binding to West Nile virus.

101 ls of 50 and 100 Envs either to characterize cross-reactive breadth for sera identified as having pot

102 sort for cells that are recognized by trimer cross-reactive broadly neutralizing antibody (bnAb) and

103 nding patches, explaining its role as both a cross-reactive but cytokine-specific receptor.

104 antigenic sin fashion and produce much more cross-reactive but less potent antibodies.

105 Anti-FLE antibodies are broadly cross-reactive but poorly neutralizing, displaying a str

106 re excluded from the study because they were cross-reactive carbohydrate determinant reactors.

107 Cross-reactive carbohydrate determinants (CCDs) in plant

108 Instead, IgE responses to ubiquitous cross-reactive carbohydrate determinants (CCDs) on plant

109 As IgE glyco-epitopes, also referred to as cross-reactive carbohydrate determinants (CCDs), can sha

110 f different natural allergens, the so-called cross-reactive carbohydrate determinants (CCDs).

111 i-SmSEA antibodies, suggesting it was due to cross-reactive carbohydrate determinants (CCDs).

112 two distinct intact IgE with specificity for cross-reactive carbohydrate determinants and Der p 2 as

113 ur immunological scenarios for the impact of cross-reactive CD4(+) memory T cells on COVID-19 severit

114 epeated annual influenza vaccination on both cross-reactive CD4+ and CD8+ T cells has not been explor

115 Cross-reactive CD8 responses elicited by vaccination wer

116 Our data show that cross-reactive CD8 T cells are infrequent during the acu

117 ZIKV/DENV cross-reactive CD8(+) T cells in DENV-immune mice expand

118 without compromising the induction of robust cross-reactive CD8+ T cell responses upon exposure to vi

119 plicating a preferential selection of shared cross-reactive CDR3betas during repertoire formation.

120 sponsive animals support a critical role for cross-reactive central memory T cells in viremia control

121 ochondrial autoantigen of PBC and xenobiotic cross reactive chemicals.

122 ay even favor the expansion and dominance of cross-reactive clones, but only when conflicting selecti

123 Although some cross-reactive dengue virus (DENV)-specific antibodies c

124 ith cockroach allergen, we observed that non-cross-reactive epitope predominantly determined IgE bind

125 After unblinding, a Leishmania cross-reactive epitope was identified and removed from t

126 results identify ZIKV-specific and ZIKV/DENV cross-reactive epitopes and demonstrate both an altered

127 vaccinations for related pathogens and that cross-reactive epitopes and TCRs may be useful for multi

128 Cross-reactive epitopes bind with higher affinity to alp

129 ion of mice with ZIKV-specific and ZIKV/DENV cross-reactive epitopes elicited CD8(+) T cell responses

130 Discovery of cross-reactive epitopes is critical to moving vaccine ca

131 the engineered immunogens should have their cross-reactive epitopes masked, and they should be optim

132 C-terminal region of DENV NS1 in which host-cross-reactive epitopes reside.

133 B/T-cross-reactive epitopes were mapped using milk-specific

134 y-m-Bd-30K soy-derived peptide that contains cross-reactive epitopes with bovine caseins.

135 ied the DENV NS1 by replacing the C-terminal cross-reactive epitopes with the corresponding region of

136 Having cross-reactive epitopes, the fusion protein also induces

137 , which were either cashew unique epitope or cross-reactive epitopes.

138 n explicit aim to reduce the exposure of the cross-reactive epitopes.

139 Several T-cell clones were cross-reactive, especially clones that recognized epitop

140 et v 1, the major birch pollen allergen, its cross-reactive food allergens, and profilins.

141 neutralizing antibody specificities that are cross-reactive for VACV, CPXV, MPXV, and VARV and that a

142 nonvaccine peptides accurately distinguishes cross-reactive from non-cross-reactive peptides.

143 trates for CB6 click that do not contain any cross-reactive functional groups and by optimizing react

144 ope binding affinities were mapped for human cross-reactive GAS proteins, including M5 and M6.

145 PV and 38.37% (95% CI = 12.68-56.51) against cross-reactive genotypes (HPV 31, 33, 45), respectively.

146 Furthermore, group cross-reactive (GR)-antibody-ablated homologous fusion p

147 imothy grass pollen allergen, belongs to the cross-reactive group 1 grass pollen allergens that are t

148 Importantly, higher cross-reactive haemagglutination-inhibition antibody tit

149 ogous prime-boost vaccination induced modest cross-reactive HI antibody responses to H5Nx viruses.

150 hat breaching peripheral tolerance permits a cross-reactive HIV-1 autoantibody response able to neutr

151 +) T cells from DENV-infected mice, and five cross-reactive HLA-B*0702-binding peptides were identifi

152 n this study, we discover and characterize a cross-reactive human IgA monoclonal antibody, MAb362.

153 SA inhibition results showing that, although cross-reactive human IgE epitopes exist, there are uniqu

154 n children may offer some protection, due to cross-reactive humoral immunity and T cell immunity betw

155 Such cross-reactive humoral immunity may provide vital first-

156 f mold allergy, and determination of a major cross-reactive IgE-epitope has clinical potential for th

157 So far, no precise information on cross-reactive IgE-epitopes of cyclophilins is available

158 t v 1 SLIT induced Bet v 1-specific, Mal d 1-cross-reactive IgG antibodies with limited cross-blockin

159 munization of mice and rabbits, MBC4 induced cross-reactive IgG antibodies, which were able to block

160 n by LJM17 from L. longipalpis-elicited DSG1-cross-reactive IgG4 antibodies may lead to FS in genetic

161 cal aspects and implications of pre-existing cross-reactive immune memory to SARS-CoV-2, which largel

162 ine may have the added benefit of inducing a cross-reactive immune response to viral strains not foun

163 sess the magnitude and functional quality of cross-reactive immune responses between these closely re

164 We predict the absence of cross-reactive immune responses for 79% of the DNA-targe

165 The cross-reactive immune responses frequently align with em

166 se data demonstrate that M type-specific and cross-reactive immune responses occur following skin inf

167 phoidal serovar, Salmonella Typhi, generates cross-reactive immune responses, which provide far great

168 commercial CIV H3N8 IIV but provided limited cross-reactive immunity and heterologous protection agai

169 ld-type C57BL/6 mice infected with ZIKV have cross-reactive immunity to subsequent ZIKV infection and

170 multiple amphibian species, possibly through cross-reactive immunity.

171 as been a challenge given preexisting, often cross-reactive, immunity and in particular, poorly immun

172 This analysis focused on long-term cross-reactive immunogenicity against nonvaccine human p

173 nto chickens, the HN13-derived antiserum was cross-reactive in immunoblots with all tested 32 field i

174 n, gut-derived IgA monoclonal antibodies are cross-reactive in the sense that they bind to multiple b

175 Cross-reactive influenza virus-specific antibody-depende

176 used for future campaigns to develop species cross-reactive inhibitors of VISTA.

177 k for structure-based drug design of broadly cross-reactive inhibitors targeting NoVs.

178 e neutralizing antibodies were detected, but cross-reactive interferon-gamma-secreting T cells were d

179 f fully human IsdA and IsdH mAbs, as well as cross-reactive Isd mAbs.

180 were highly variable, numerous instances of cross-reactive killing were observed.

181 Serology is cross-reactive, laborious, and frequently difficult to i

182 Der p 1-specific mAbs 5H8 and 10B9, and the cross-reactive mAb 4C1.

183 dy therapy for NiV and HeV using a humanized cross-reactive mAb targeting the F glycoprotein, and the

184 e a structural and molecular mechanism for a cross-reactive mAb that uniquely neutralizes ZIKV and DE

185 However, the cross-reactive MAbs had functional activities limited to

186 d that the RV-A15-specific mAbs, but not the cross-reactive mAbs, had neutralizing activity against R

187 led substantial ADCP activity for one of the cross-reactive mAbs.

188 ; the H. influenzae protein D (HiD); and the cross-reactive material from diphtheria toxin (CRM197).

189 covery of infused BeneFix (FIX(WT)) in null (cross-reactive material negative, CRM(-)) hemophilia B m

190 engue virus elicits robust type-specific and cross-reactive MBC responses after primary and secondary

191 Dengue virus infection also induced cross-reactive MBC responses recognizing ZIKV, particula

192 fections does not influence type-specific or cross-reactive MBC responses, although ZIKV has the high

193 DENV cross-reactive MBCs expanded by ZIKV infection decline i

194 requency and proportion of type-specific and cross-reactive MBCs were comparable between primary and

195 both high-quality neoantigens and predicted cross-reactive microbial epitopes, consistent with neoan

196 antibodies, specifically the two identified cross-reactive monoclonal antibodies (KL-2E5 and KL-2H7)

197 of somatic hypermutation and encoded broadly cross-reactive monoclonal antibodies.

198 Human myosin cross-reactive N-terminal and B repeat epitopes of GAS M

199 d to characterize the potency and breadth of cross-reactive neutralization by monoclonal antibodies,

200 , with envelope (Env)-trimer boosts inducing cross-reactive neutralization.

201 esponse comprising very potent and extremely cross-reactive neutralizing antibodies [broadly neutrali

202 three viral challenges and produced broadly cross-reactive neutralizing antibodies to H2 influenza v

203 Cross-reactive neutralizing antibodies to the RSV and HM

204 The induction of similar cross-reactive neutralizing antibodies using structural

205 No cross-reactive neutralizing antibodies were detected, bu

206 In preimmune subjects, CYD-TDV boosted cross-reactive neutralizing antibodies while maintaining

207 nd characterized a panel of vaccine-elicited cross-reactive neutralizing MAbs targeting the Env V3 lo

208 al studies demonstrated that the most potent cross-reactive neutralizing mAbs, HENV-26 and HENV-32, p

209 we isolated, characterized, and humanized a cross-reactive, neutralizing anti-F mAb (h5B3.1).

210 ion in ferrets and non-human primates with a cross-reactive, neutralizing human monoclonal antibody (

211 anced in the presence of sub-neutralizing or cross-reactive non-neutralizing antiviral antibodies.

212 we report the characterization of 22 broadly cross-reactive, nonneutralizing antibodies specific for

213 se might be diverted from one site to a more cross-reactive one, which would help in the induction of

214 Cross-reactive peptides for these TCRs were previously i

215 Here we isolated cross-reactive peptides with limited homology, which all

216 rately distinguishes cross-reactive from non-cross-reactive peptides.

217 resents an obstacle in the identification of cross-reactive peptides.

218 TCR-pMHC complexes to predict the binding of cross-reactive peptides.

219 the related dengue virus is the induction of cross-reactive poorly neutralizing antibodies that can c

220 seasonally circulating coronaviruses induce cross-reactive, potentially even cross-neutralizing, ant

221 recognized by virus-specific and flavivirus cross-reactive potently neutralizing antibodies that hav

222 Our study demonstrated that cross-reactive primary virus neutralizing B cell lineage

223 Javiana or its toxin offers cross-reactive protection against lethal-dose typhoid to

224 avian influenza (H5N1) virus elicits robust, cross-reactive protection from influenza virus infection

225 While broadly cross-reactive, protective monoclonal antibodies against

226 ng capsule-based vaccination with conserved, cross-reactive protein-based vaccines broadens and enhan

227 Cross-reactive rabbit anti-SmSEA IgG antibodies eluted f

228 led three structural epitopes: two partially cross-reactive regions around alpha-helices 2 and 4 as w

229 m MCMV-immune mice mount a robust CD8 T cell cross-reactive response between a newly defined putative

230 se differences may contribute to the broadly cross-reactive response elicited by HN13.

231 DENV infection, with a significantly higher cross-reactive response in both.

232 ry and secondary DENV infections, within the cross-reactive response, the breadth of MBC responses ag

233 The understanding of how cross-reactive responses develop is essential for the ra

234 f fHbp in N. cinerea and N. meningitidis and cross-reactive responses elicited by Bexsero suggest tha

235 e protein have been hampered by concerns for cross-reactive responses that induce antibody-dependent

236 iple flaviviruses; however, the magnitude of cross-reactive responses was consistently severalfold lo

237 Moreover, in the uncommon instances where cross-reactive responses were detected, the variant epit

238 And while depth, or the frequency of cross-reactive responses, did not correlate with viral l

239 alysis provides insight into the presence of cross-reactive responses.

240 stitute a potential new source of primary or cross-reactive sensitization to lupin, particularly to L

241 , the single sensor device integrated in the cross-reactive sensor matrix exhibits multimodal detecti

242 Here, a highly stretchable cross-reactive sensor matrix is demonstrated, which can

243 e responses to highly penetrant viruses with cross-reactive serotypes.

244 al influenza virus vaccine regimens elicited cross-reactive serum IgG antibodies that targeted the co

245 ody (2.2-5.6 times induction over baseline), cross-reactive serum IgG antibody, and peripheral blood

246 ka virus infection induced detectable Dengue cross-reactive serum IgG responses that significantly am

247 ng exposure to the offending allergen(s) and cross-reactive structures.

248 A vaccine providing both powerful Ab and cross-reactive T cell immune responses against influenza

249 sum, we argue that key potential impacts of cross-reactive T cell memory are already incorporated in

250 nexposed individuals, suggesting preexisting cross-reactive T cell memory in 20 to 50% of people.

251 uction of two completely independent and non-cross-reactive T cell populations that show distinct fun

252 40%-60% of unexposed individuals, suggesting cross-reactive T cell recognition between circulating "c

253 This results indicate that spike-protein cross-reactive T cells are present, which were probably

254 In the absence of neutralizing antibodies, cross-reactive T cells have been shown to limit disease

255 However, the presence of spike-protein cross-reactive T cells in a considerable fraction of the

256 oof of concept that LAIVs boost preexisting, cross-reactive T cells in children to genetically divers

257 The effect of pre-existing SARS-CoV-2 cross-reactive T cells on clinical outcomes remains to b

258 unity to related flaviviruses could generate cross-reactive T cells that may affect immune responses

259 Preexisting cross-reactive T cells to genetically diverse IAV strain

260 he use of LAIV in children to elicit broadly cross-reactive T cells, which are not induced by traditi

261 We studied the long-term cross-reactive T-cell response in 14 trivalent LAIV-vacc

262 LAIV boosts durable, cross-reactive T-cell responses in children and may have

263 pratense, as well as their ability to induce cross-reactive T-cell responses.

264 cord with the observations that pre-existing cross-reactive T-cells correlate with protection in huma

265 f a soy-peptide-containing an immunodominant cross-reactive T-epitope, along with a single B epitope,

266 A) protein can be protective and are broadly cross-reactive, the immune response to NA during infecti

267 ) responses, as well as weak and/or sporadic cross-reactive tier 2 virus NAb responses with unknown s

268 elineate the specificity of vaccine-elicited cross-reactive tier 2 virus NAb responses, we performed

269 3-specific MAbs, nearly 20% (6/33) displayed cross-reactive tier 2 virus neutralization, which recapi

270 Mouse anti-B. burgdorferi serum was cross-reactive to all recombinant Vlps, but not against

271 uster IV A(H3N2)v vaccine induced antibodies cross-reactive to cluster 2010.1 viruses in about 1/3 of

272 uster IV A(H3N2)v vaccine induced antibodies cross-reactive to cluster 2010.1 viruses in approximatel

273 T-cell lines were highly cross-reactive to epitopes of related ragweed species wi

274 Ab raised to a modified survivin peptide but cross-reactive to survivin.

275 The M protein was highly cross-reactive to TGEV and PRCV antisera.

276 A significant increase in cross-reactive tonsillar CD8+ T cells recognizing conser

277 golipids and phospholipids, but were broadly cross-reactive towards diverse phospholipids including p

278 itope, and our attempts to rationally design cross-reactive trimers resulted in only limited success.

279 ology were observed between selected macaque cross-reactive V3 NAbs elicited by vaccination and proto

280 Striking similarities between the cross-reactive V3 NAbs elicited by vaccination in macaqu

281 H and SARS-CoV-2 S and demonstrate that this cross-reactive VHH neutralizes SARS-CoV-2 S pseudotyped

282 The cross-reactive VHHs block binding of EF/LF to the protec

283 cephalitis NS1, a homologous and potentially cross-reactive viral antigen.

284 R was identified as a high affinity, species cross-reactive VNAR antibody against TfR1-ECD that does

285 es and found that the synbodies were broadly cross-reactive with affinities that ranged from 0.5 to 8

286 fection with TBRF agents produces antibodies cross-reactive with B. burgdorferi assays.

287 ria/2/1987-like lineage, and two were highly cross-reactive with B/Yamagata/16/1988-like lineage viru

288 at systemic and lung mucosal immunoglobulins cross-reactive with beta-glucan and chitosan/chitin are

289 Notably, lung mucosal quantities of IgA cross-reactive with beta-glucan or chitosan/chitin are d

290 l depletion did not impact quantities of IgG cross-reactive with beta-glucan or chitosan/chitin in th

291 ls was low and dominated by clones that were cross-reactive with both Ebola glycoprotein (GP) and wit

292 f preexisting memory CD4(+) T cells that are cross-reactive with comparable affinity to SARS-CoV-2 an

293 MSB0010853 is cross-reactive with HER3 and albumin of mouse origin.

294 DENV nonstructural protein 1 (NS1) which are cross-reactive with host Ags and trigger anti-DENV NS1 A

295 naturally processed cancer antigens that are cross-reactive with microbial peptides were detected.

296 FM15-35 Although NFM15-35 is immunogenic and cross-reactive with MOG at the polyclonal level, it fail

297 g the acute phase of infection and are often cross-reactive with similar pathogenic and nonpathogenic

298 The 19 mammalian Wnt proteins are cross-reactive with the 10 FZD receptors, and this has c

299 gp41 membrane proximal region (MPER) and is cross-reactive with the HIV broadly neutralizing Ab (bnA

300 e whether an anti-Ebola virus sdAb, that was cross-reactive within the Ebolavirus genus, recognized a